Abstract
Prostate cancer is the most commonly diagnosed malignancy in American men. Developing gene therapy for prostate cancer is important, because there is no effective treatment for patients in the advanced stages of this disease. A tissue-specific promoter to transcriptionally target cancer cells is a promising approach for gene therapy of prostate cancer. We previously constructed a prostate tissue-specific promoter based on the proximal promoter and the upstream regulatory sequence of the prostate-specific antigen gene. In the experiments described here, we modified our prostate-specific promoter to drive the A domain of the diphtheria toxin gene (DTA) in a plasmid vector. The plasmid vector can be efficiently transfected into cell lines, using a liposome-mediated transfection method. In the transfected prostate cell line, LNCaP, the DTA gene was actively transcribed, and significant inhibition of protein synthesis and cytopathic effects was observed. However, no pathogenic effects were apparent in the control cell lines. The highly specific and efficient cytopathicity of the DTA gene vector is therefore potentially useful for systemic treatment of patients with metastatic prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pang, S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther 7, 991–996 (2000). https://doi.org/10.1038/sj.cgt.7700197
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700197
Keywords
This article is cited by
-
Oncolytic viral therapies
Cancer Gene Therapy (2004)
-
Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A
Cancer Gene Therapy (2003)
-
Prostate-specific targeting using PSA promoter-based lentiviral vectors
Cancer Gene Therapy (2001)
-
Endothelial cell–based systemic gene therapy of metastatic melanoma
Cancer Gene Therapy (2001)